Handel First Wave BioPharma, Inc. - FWBI CFD
Føj til favorit- Opsummering
- Historisk Data
- Begivenheder
- Resultatopgørelse
- Saldo
- Cash flow
- Ejerskab
Handelsbetingelser
| Spænd | 0.1114 | ||||||||
|
Long position, gebyr natten over
Long position overnight fee
Gå til platform | -0.024068% | ||||||||
|
Short position, gebyr natten over
Short position overnight fee
Gå til platform | 0.001846% | ||||||||
| Gebyr natten over, tid | 21:00 (UTC) | ||||||||
| Min. handlet mængde | 0.001 | ||||||||
| Valuta | USD | ||||||||
| Margen | 20% | ||||||||
| Aktiebørs | United States of America | ||||||||
| Kommission på handel | 0% |
*Information provided by Capital.com
Nøglestatistikker
| Tidligere luk* | 3.1678 |
| Åben* | 3.1673 |
| 1-Års Ændring* | 193.27% |
| Dagens Spænd* | 2.9986 - 3.1673 |
| 52-Ugers Spænd | 2.76-289.80 |
| Gennemsnitlig Volumen (10 dage) | 120.97K |
| Gennemsnitlig Volumen (3 måneder) | 11.19M |
| Market Cap | 4.97M |
| P/E-forhold | -100.00K |
| Udestående aktier | 1.55M |
| Omsætning | N/A |
| EPS | -248.68 |
| Dividend (Udbytte %) | N/A |
| Beta | 1.69 |
| Næste indtjeningsopgørelse | N/A |
Al data kommer fra Refinitiv, med undtagelse af data markeret med en asterisk, som er *data fra Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Luk | Change | Change (%) | Åben | High | Low |
|---|---|---|---|---|---|---|
| Mar 22, 2023 | 3.0193 | -0.0990 | -3.17% | 3.1183 | 3.1774 | 2.9687 |
| Mar 21, 2023 | 3.1678 | 0.0892 | 2.90% | 3.0786 | 3.1678 | 3.0582 |
| Mar 20, 2023 | 3.0588 | 0.0499 | 1.66% | 3.0089 | 3.1283 | 2.9691 |
| Mar 17, 2023 | 3.0291 | 0.0600 | 2.02% | 2.9691 | 3.0391 | 2.9591 |
| Mar 16, 2023 | 2.9695 | 0.1986 | 7.17% | 2.7709 | 3.0093 | 2.7704 |
| Mar 15, 2023 | 2.9302 | 0.1883 | 6.87% | 2.7419 | 2.9302 | 2.6917 |
| Mar 14, 2023 | 2.7715 | -0.1685 | -5.73% | 2.9400 | 2.9400 | 2.6912 |
| Mar 13, 2023 | 3.0191 | -0.5440 | -15.27% | 3.5631 | 3.5731 | 2.9982 |
| Mar 10, 2023 | 3.6238 | 0.0103 | 0.29% | 3.6135 | 3.6634 | 3.5640 |
| Mar 9, 2023 | 3.7131 | -0.2472 | -6.24% | 3.9603 | 4.1786 | 3.5639 |
| Mar 8, 2023 | 3.5246 | -0.0395 | -1.11% | 3.5641 | 3.6041 | 3.4648 |
| Mar 7, 2023 | 3.5148 | -0.0593 | -1.66% | 3.5741 | 3.7130 | 3.5047 |
| Mar 6, 2023 | 3.6437 | 0.0800 | 2.24% | 3.5637 | 3.7130 | 3.5637 |
| Mar 3, 2023 | 3.6436 | 0.1790 | 5.17% | 3.4646 | 3.7723 | 3.4646 |
| Mar 2, 2023 | 3.5146 | 0.0496 | 1.43% | 3.4650 | 3.5546 | 3.4650 |
| Mar 1, 2023 | 3.5346 | 0.0200 | 0.57% | 3.5146 | 3.5645 | 3.4650 |
| Feb 28, 2023 | 3.4750 | 0.1891 | 5.75% | 3.2859 | 3.5248 | 3.2856 |
| Feb 27, 2023 | 3.4157 | -0.2371 | -6.49% | 3.6528 | 3.7229 | 3.3658 |
| Feb 24, 2023 | 3.6733 | 0.0595 | 1.65% | 3.6138 | 3.7923 | 3.5241 |
| Feb 23, 2023 | 3.7228 | -0.0391 | -1.04% | 3.7619 | 3.7924 | 3.6632 |
First Wave BioPharma, Inc. Events
| Tid (UTC) (UTC) | Land | Begivenhed |
|---|---|---|
| No events scheduled | ||
- Årlig
- Pr kvartal
| 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|
| Total omsætning | 0 | 0 | 0 | 0 | 0 |
| Totale Driftsudgifter | 59.0569 | 26.8313 | 14.7437 | 13.4318 | 10.2212 |
| Salgs/Generelle/Admin. Udgifter, Total | 18.3696 | 7.27976 | 6.04227 | 8.17431 | 6.93171 |
| Forskning & Udvikling | 38.3204 | 19.105 | 7.85849 | 4.98555 | 2.39548 |
| Depreciation / Amortization | 0.015 | 0.048 | 0.84299 | 0.06191 | 0.754 |
| Other Operating Expenses, Total | 0 | 0.21 | 0.14 | ||
| Driftsindtægter | -59.0569 | -26.8313 | -14.7437 | -13.4318 | -10.2212 |
| Renteindkomst (Udgift), Netto Ikke-Drift | -0.01007 | -5.84013 | -0.43394 | -0.10185 | -0.8752 |
| Andre, Netto | 0.5291 | 0 | |||
| Netto Indkomst Før Skat | -58.5378 | -32.6715 | -15.1777 | -13.5336 | -11.0964 |
| Netto Indkomst Efter Skat | -58.5378 | -32.6715 | -15.1777 | -13.5336 | -11.0964 |
| Netto Indkomst Før Ekstra Ting | -58.5378 | -32.6715 | -15.1777 | -13.5336 | -11.0964 |
| Netto Indkomst | -58.5378 | -32.6715 | -15.1777 | -13.5336 | -11.0964 |
| Indkomst Tilgængelig for Almindelige Uden Ekstra Ting | -84.5186 | -41.7323 | -15.1777 | -13.5336 | -11.0964 |
| Indkomst Tilgængelig for Almindelige Uden Ekstra Ting | -84.5186 | -41.7323 | -15.1777 | -13.5336 | -11.0964 |
| Fortyndet Netto Indkomst | -84.5186 | -41.7323 | -15.1777 | -13.5336 | -11.0964 |
| Fortyndet Vægtet Gennemsnit Aktier | 8.92573 | 2.84363 | 2.24256 | 1.54393 | 1.06288 |
| Fortyndet EPS Uden Ekstraordinære Ting | -9.4691 | -14.6757 | -6.76803 | -8.76569 | -10.4399 |
| Fortyndet Normaliseret EPS | -9.20559 | -14.5356 | -6.76803 | -8.76569 | -10.4399 |
| Omsætning | 0 | ||||
| Usædvanlig Udgift (Indkomst) | 2.35199 | 0.39857 | |||
| Total Adjustments to Net Income | -25.9807 | -9.06087 |
| Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
|---|---|---|---|---|---|
| Total omsætning | 0 | 0 | 0 | 0 | 0 |
| Totale Driftsudgifter | 9.38207 | 11.167 | 30.3995 | 9.27689 | 8.21354 |
| Salgs/Generelle/Admin. Udgifter, Total | 4.40556 | 3.03678 | 6.02116 | 3.62809 | 5.69751 |
| Forskning & Udvikling | 4.97652 | 5.77821 | 24.3783 | 5.6468 | 2.51503 |
| Depreciation / Amortization | 0.002 | 0.001 | |||
| Driftsindtægter | -9.38207 | -11.167 | -30.3995 | -9.27689 | -8.21354 |
| Renteindkomst (Udgift), Netto Ikke-Drift | -0.00547 | -0.00123 | -0.00074 | -0.00295 | -0.00474 |
| Andre, Netto | -0.2393 | -0.00428 | -0.00057 | 0.0009 | 0.53265 |
| Netto Indkomst Før Skat | -9.62684 | -11.1725 | -30.4008 | -9.27894 | -7.68563 |
| Netto Indkomst Efter Skat | -9.62684 | -11.1725 | -30.4008 | -9.27894 | -7.68563 |
| Netto Indkomst Før Ekstra Ting | -9.62684 | -11.1725 | -30.4008 | -9.27894 | -7.68563 |
| Netto Indkomst | -9.62684 | -11.1725 | -30.4008 | -9.27894 | -7.68563 |
| Total Adjustments to Net Income | -0.68577 | -0.11623 | -0.11809 | -3.45087 | -22.2956 |
| Indkomst Tilgængelig for Almindelige Uden Ekstra Ting | -10.3126 | -11.2887 | -30.5189 | -12.7298 | -29.9812 |
| Indkomst Tilgængelig for Almindelige Uden Ekstra Ting | -10.3126 | -11.2887 | -30.5189 | -12.7298 | -29.9812 |
| Fortyndet Netto Indkomst | -10.3126 | -11.2887 | -30.5189 | -12.7298 | -29.9812 |
| Fortyndet Vægtet Gennemsnit Aktier | 15.5447 | 12.9223 | 9.34236 | 7.81244 | 5.53481 |
| Fortyndet EPS Uden Ekstraordinære Ting | -0.66342 | -0.87359 | -3.26672 | -1.62943 | -5.41684 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Fortyndet Normaliseret EPS | -0.66342 | -0.69158 | -3.26672 | -1.62943 | -5.41684 |
| Usædvanlig Udgift (Indkomst) | 2.35199 |
- Årlig
- Pr kvartal
| 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|
| Totale Nuværende Aktiver | 9.42495 | 7.86978 | 3.40829 | 4.8 | 1.95257 |
| Likvider og Kortsigtede Investeringer | 8.24868 | 6.06214 | 0.1758 | 1.11434 | 0.57347 |
| Cash | 8.24868 | 6.06214 | 0.1758 | 1.11434 | 0.57347 |
| Kortsigtede Investeringer | |||||
| Totale Tilgodehavender, Netto | 0 | 0.55149 | 2.6373 | 3.17268 | 1.10413 |
| Prepaid Expenses | 1.17627 | 1.25615 | 0.59519 | 0.51298 | 0.27496 |
| Total Assets | 11.79 | 12.9239 | 8.90288 | 7.4694 | 5.47967 |
| Property/Plant/Equipment, Total - Net | 0.40931 | 0.09257 | 0.15978 | 0.12885 | 0.13399 |
| Goodwill, Net | 1.91171 | 2.05405 | 1.88669 | 1.92483 | 2.01624 |
| Intangibles, Net | 0 | 2.87954 | 3.40708 | 0.57048 | 1.34596 |
| Other Long Term Assets, Total | 0.04401 | 0.02792 | 0.04105 | 0.04523 | 0.03092 |
| Total Current Liabilities | 12.3004 | 15.5454 | 4.28564 | 2.99552 | 2.47908 |
| Payable/Accrued | 0 | 0.53343 | 0.6701 | 2.05534 | |
| Accrued Expenses | 0.49706 | 0.18443 | 0.15441 | 0.53829 | 0.00719 |
| Notes Payable/Short Term Debt | 0.64124 | 0.55241 | 1.5213 | 0.25503 | 0.41655 |
| Other Current Liabilities, Total | 8.48018 | 13.25 | 0.39299 | ||
| Total Liabilities | 19.6115 | 15.5646 | 4.28564 | 2.99552 | 3.81908 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Liabilities, Total | 7.31114 | 0.01912 | 0 | 0 | 1.34 |
| Total Equity | -7.82155 | -2.64069 | 4.61724 | 4.47387 | 1.66059 |
| Common Stock | 0.00149 | 0.00312 | 0.00268 | 0.00177 | 0.00121 |
| Additional Paid-In Capital | 147.305 | 93.8349 | 68.5759 | 53.1393 | 37.6696 |
| Retained Earnings (Accumulated Deficit) | -153.904 | -95.3662 | -62.6947 | -47.5171 | -33.9834 |
| Other Equity, Total | -1.22414 | -1.11255 | -1.26656 | -1.15011 | -2.02679 |
| Total Liabilities & Shareholders’ Equity | 11.79 | 12.9239 | 8.90288 | 7.4694 | 5.47967 |
| Total Common Shares Outstanding | 14.8559 | 3.11503 | 2.68005 | 1.77049 | 1.20426 |
| Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | 0 |
| Property/Plant/Equipment, Total - Gross | 0.42402 | 0.13097 | 0.4233 | 0.33225 | |
| Accumulated Depreciation, Total | -0.01471 | -0.0384 | -0.26352 | -0.20339 | |
| Accounts Payable | 2.68191 | 1.55859 | 1.68351 | 1.53211 |
| Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
|---|---|---|---|---|---|
| Totale Nuværende Aktiver | 6.55017 | 9.42495 | 7.50249 | 8.61528 | 13.1704 |
| Likvider og Kortsigtede Investeringer | 5.69499 | 8.24868 | 7.21065 | 8.07449 | 12.0256 |
| Cash | 5.69499 | 8.24868 | 7.21065 | 8.07449 | 12.0256 |
| Totale Tilgodehavender, Netto | 0.02806 | 0 | 0 | 0 | 0.50166 |
| Prepaid Expenses | 0.82713 | 1.17627 | 0.29184 | 0.54079 | 0.64313 |
| Total Assets | 8.82544 | 11.79 | 12.424 | 13.7768 | 17.9829 |
| Property/Plant/Equipment, Total - Net | 0.3788 | 0.40931 | 0.44889 | 0.48488 | 0.06162 |
| Property/Plant/Equipment, Total - Gross | 0.40083 | 0.42402 | 0.45632 | 0.4861 | 0.0812 |
| Accumulated Depreciation, Total | -0.02203 | -0.01471 | -0.00743 | -0.00123 | -0.01958 |
| Goodwill, Net | 1.86207 | 1.91171 | 1.94474 | 1.99129 | 1.97396 |
| Intangibles, Net | 0 | 2.48388 | 2.61576 | 2.74765 | |
| Other Long Term Assets, Total | 0.0344 | 0.04401 | 0.04403 | 0.0696 | 0.02924 |
| Total Current Liabilities | 14.2157 | 12.3004 | 19.0983 | 6.45412 | 3.57464 |
| Accounts Payable | 3.44993 | 2.68191 | 18.4478 | 4.44991 | 1.44072 |
| Accrued Expenses | 0.7883 | 0.49706 | 0.22987 | 0.31246 | 0.32383 |
| Notes Payable/Short Term Debt | 0.40277 | 0.64124 | 0 | 0.13957 | 0.34708 |
| Other Current Liabilities, Total | 9.57473 | 8.48018 | 0.42063 | 1.55218 | 1.46302 |
| Total Liabilities | 18.0652 | 19.6115 | 19.394 | 6.73988 | 3.58121 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Liabilities, Total | 3.8495 | 7.31114 | 0.29569 | 0.28575 | 0.00657 |
| Total Equity | -9.23979 | -7.82155 | -6.96999 | 7.03692 | 14.4017 |
| Common Stock | 0.00215 | 0.00149 | 0.00111 | 0.00826 | 0.00749 |
| Additional Paid-In Capital | 155.571 | 147.305 | 137.028 | 120.585 | 118.693 |
| Retained Earnings (Accumulated Deficit) | -163.531 | -153.904 | -142.732 | -112.331 | -103.052 |
| Other Equity, Total | -1.28254 | -1.22414 | -1.26711 | -1.2255 | -1.24734 |
| Total Liabilities & Shareholders’ Equity | 8.82544 | 11.79 | 12.424 | 13.7768 | 17.9829 |
| Total Common Shares Outstanding | 21.5488 | 14.8559 | 11.1152 | 8.25851 | 7.49269 |
| Preferred Stock - Non Redeemable, Net | 0 |
- Årlig
- Pr kvartal
| 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|
| Netto indkomst/Startlinje | -58.5378 | -32.6715 | -15.1777 | -13.5336 | -11.0964 |
| Likvider Fra Driftsaktiviteter | -32.2882 | -11.2215 | -14.0335 | -10.8693 | -7.18464 |
| Likvider Fra Driftsaktiviteter | 0.01471 | 0.0378 | 0.0631 | 0.06191 | 0.04952 |
| Amortization | 0.52755 | 0.52755 | 0.95695 | 0.73654 | 0.70448 |
| Ikke-Likvide Ting | 8.60641 | 6.73365 | 1.82513 | 3.57765 | 3.42595 |
| Ændringer i Driftskapital | 17.101 | 14.1509 | -1.70099 | -1.7118 | -0.26821 |
| Likvider fra Investeringsaktiviteter | -10.3195 | 0.08735 | -0.0241 | -0.30547 | -0.03217 |
| Kapitaludgifter | -0.06949 | -0.00417 | -0.0241 | -0.30547 | -0.03217 |
| Likvider fra Financieringsaktiviteter | 44.7635 | 17.0461 | 13.145 | 11.7121 | 6.01322 |
| Financiering af Cash-Flow-Ting | 0 | ||||
| Udstedelse (Pensionering) af Aktier, Netto | 44.6747 | 14.1861 | 9.53834 | 11.9028 | 5.00923 |
| Udstedelse (Pensionering) af Gæld, Netto | 0.08883 | 2.86003 | 3.60664 | -0.19068 | 1.00399 |
| Udenlandsk Børs Effekter | 0.03076 | -0.02559 | -0.02593 | 0.00354 | 0.00353 |
| Netto Ændring i Likviditet | 2.18654 | 5.88635 | -0.93855 | 0.54087 | -1.20005 |
| Cash Taxes Paid | 0 | 0 | 0 | 0 | |
| Likvid Rente Betalt | 0 | 0.10546 | 0.00803 | 0.00401 | 0.00415 |
| Andre Investerings-Cash-Flow-Ting, Total | -10.25 | 0.09152 |
| Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -9.62684 | -58.5378 | -47.3654 | -16.9646 | -7.68563 |
| Cash From Operating Activities | -7.91207 | -32.2882 | -26.4254 | -10.6961 | -5.07339 |
| Cash From Operating Activities | 0.00732 | 0.01471 | 0.00939 | 0.00301 | 0.00102 |
| Amortization | 0 | 0.52755 | 0.39566 | 0.26377 | 0.13189 |
| Non-Cash Items | 0.36042 | 8.60641 | 2.04186 | 1.7359 | 1.80638 |
| Cash Interest Paid | 0 | 0 | 0 | 0 | 0.00514 |
| Changes in Working Capital | 1.34703 | 17.101 | 18.493 | 4.26576 | 0.67294 |
| Cash From Investing Activities | -10.3195 | -10.3215 | -9.07393 | 0 | |
| Capital Expenditures | -0.06949 | -0.07145 | -0.07393 | 0 | |
| Cash From Financing Activities | 5.36715 | 44.7635 | 37.9406 | 21.8326 | 11.0506 |
| Financing Cash Flow Items | -2.41496 | -9.53235 | |||
| Issuance (Retirement) of Stock, Net | 8.02057 | 44.6747 | 38.493 | 22.2454 | 20.7883 |
| Issuance (Retirement) of Debt, Net | -0.23847 | 0.08883 | -0.55241 | -0.41284 | -0.20532 |
| Foreign Exchange Effects | -0.00877 | 0.03076 | -0.04525 | -0.05019 | -0.01374 |
| Net Change in Cash | -2.5537 | 2.18654 | 1.1485 | 2.01235 | 5.96349 |
| Cash Taxes Paid | 0 | 0 | 0 | ||
| Other Investing Cash Flow Items, Total | -10.25 | -10.25 | -9 |
| Investornavn | Investortype | Procent udestående | Aktiebeholdning | Aktieændring | Beholdningsdato | IOmsætningsscore |
|---|---|---|---|---|---|---|
| Sapirstein (James E) | Individual Investor | 4.3072 | 42857 | 42857 | 2023-01-03 | HIGH |
| Armistice Capital LLC | Hedge Fund | 4.2206 | 41995 | 41995 | 2022-12-31 | HIGH |
| Romano (Sarah M.) | Individual Investor | 2.1537 | 21429 | 21429 | 2023-01-03 | MED |
| Hoffman (David Andrew) | Individual Investor | 1.3033 | 12968 | 12106 | 2023-01-03 | HIGH |
| Borkowski (Edward J) | Individual Investor | 1.237 | 12308 | 12106 | 2023-01-03 | |
| Riddell (Alastair) | Individual Investor | 1.223 | 12169 | 12106 | 2023-01-03 | |
| Casamento (Charles J) | Individual Investor | 1.2223 | 12162 | 12106 | 2023-01-03 | |
| Coelho (Mary Theresa) | Individual Investor | 1.2167 | 12106 | 12106 | 2023-01-03 | LOW |
| State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 1.1858 | 11799 | 0 | 2022-12-31 | LOW |
| Acadian Asset Management LLC | Investment Advisor/Hedge Fund | 0.7214 | 7178 | 7178 | 2022-12-31 | MED |
| Susquehanna International Group, LLP | Investment Advisor | 0.2193 | 2182 | 2182 | 2022-12-31 | MED |
| UBS Financial Services, Inc. | Investment Advisor | 0.2048 | 2038 | 1752 | 2022-12-31 | LOW |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.1537 | 1529 | 1529 | 2022-12-31 | LOW |
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 0.0982 | 977 | 0 | 2023-02-28 | LOW |
| Tower Research Capital LLC | Hedge Fund | 0.0975 | 970 | 497 | 2022-12-31 | HIGH |
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 0.0379 | 377 | 0 | 2022-12-31 | LOW |
| Advisor Group, Inc | Investment Advisor | 0.0287 | 286 | 286 | 2022-12-31 | LOW |
| Wells Fargo Advisors | Research Firm | 0.0027 | 27 | 0 | 2022-12-31 | LOW |
| U.S. Bancorp Asset Management, Inc. | Investment Advisor | 0.0024 | 24 | 0 | 2022-12-31 | LOW |
| BlackRock Financial Management, Inc. | Investment Advisor/Hedge Fund | 0.0022 | 22 | 0 | 2022-12-31 | LOW |
Hvorfor vælge Capital.com? Vores tal taler for sig selv.
Capital.com Group500K+
Handlende
92K+
Månedlkige, aktive klienter
$53M+
Månedlig investeringsvolumen
$30M+
Hævet hver måned
Handelslommeregner
Udregn dit hypotetiske P&L hvis du havde åbnet en CFD-handel på en given dato (vælg en dato) og lukket den på en anden dato (vælg en dato).
Handelskurtage
0
- 1:1
Gearing
1:1
- 20
- 100
- 500
- 1000
- 10000
Investering
Handelsstørrelse (Gearing x Investering):
Åben
Luk
Short Long
First Wave BioPharma, Inc. Company profile
Om First Wave BioPharma, Inc.
First Wave BioPharma, Inc. tidligere AzurRx BioPharma, Inc. er en biofarmaceutisk virksomhed i den kliniske fase. Virksomheden beskæftiger sig med udvikling af målrettede, ikke-systemiske behandlinger for gastrointestinale (GI) sygdomme. Selskabet fokuserer på at fremme en terapeutisk udviklingspipeline, der er bygget op omkring dets to teknologier: niclosamid, et oralt lille molekyle med antivirale og antiinflammatoriske egenskaber, og det biologiske adrulipase, et rekombinant lipaseenzym, der er designet til at muliggøre fordøjelsen af fedt og andre næringsstoffer. Selskabets niclosamid-portefølje ledes af tre kliniske programmer: FW-COV, for COVID-19 gastrointestinale infektioner; FW-UP, for ulcerativ proctitis (UP) og ulcerativ proctosigmoiditis; og FW-ICI-AC, for grad 1 og grad 2 immun checkpoint inhibitor-associeret colitis og diarré hos avancerede onkologipatienter. Virksomheden er også ved at udvikle FW-EPI (adrulipase) til behandling af exokrin pancreasinsufficiens (EPI) hos patienter med cystisk fibrose og kronisk pancreatitis.
| Industry: | Biotechnology & Medical Research (NEC) |
777 Yamato Road
Suite 502
BOCA RATON
FLORIDA 33431
US
Resultatopgørelse
- Annual
- Quarterly
Folk ser også
Leder du stadig efter en mægler, du kan stole på?
Deltag sammen med 500.000+ handlende over hele verden, der valgte at handle hos Capital.com